The development of efficient biologics for the treatment of psoriasis has raised questions about raising the clearance level that defines the standard of care. Be sure to attend “Psoriasis” (S008) from 9 a.m. to noon Friday in Hall D.
The symposium will open with an overview of advances in psoriasis treatment, followed by a debate on whether the new standard of care should be PASI 90 rather than PASI 75.
There also will be a discussion on future topical psoriasis therapies, the use of new oral drugs, psoriasis comorbidities, and treatment of challenging areas, including nails, scalp, palms, and soles. The session will conclude with a discussion of biosimilars.
Presentations and speakers will be:
- Introduction and Overview, Boni E. Elewski, MD
- New Systemic Therapies — IL 17 and IL 23 Drugs, Mark Lebwohl, MD
- DEBATE: Should We Throw Out PASI 75 and Replace It With PASI 90? No! PASI 75 Should Remain the Standard, Robert Bissonnette, MD, MSc
- PASI 90 Should Become the New Standard, David Pariser, MD
- What’s New in Topical Psoriasis Therapy? Linda F. Stein Gold, MD
- New Oral Psoriasis Therapies — Tofacitinib and Apremilast, Kim A. Papp, MD
- What You Need to Know about Psoriasis Comorbidities, Joel M. Gelfand, MD, MSCE
- Treatment of Problem Areas: Scalp, Genital Area, Palms and Soles, April W. Armstrong, MD, MPH
- Nail Psoriasis Diagnosis and Treatment, Boni E. Elewski, MD
- Biosimilars or Bioequivalents? What You Need to Know Now Because They Are Here! Characterization of Biosimilars to Optimize Quality and Clinical Performance, Andrew Blauvelt, MD
- Characterization of Biosimilars in the Clinical Setting, Bruce Elliot Strober, MD, PhD
- Biosimilars: How Different is Similar? Paul W. Tebbey, PhD
- Biosimilars: The Science Done Right, Primal Kaur, MD